What is China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (300294.SZ) StockRank?

MoatMap's StockRank for China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) is 16/100, with a Strong Sell signal. This is a composite score combining Quality (48), Value (31), and Momentum (25) factor ranks across MoatMap's 19,000+ stock universe.

Does China Resources Boya Bio-pharmaceutical Group Co.,Ltd have an economic moat?

China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is China Resources Boya Bio-pharmaceutical Group Co.,Ltd a buy, hold, or sell?

MoatMap's current signal for China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is China Resources Boya Bio-pharmaceutical Group Co.,Ltd in?

China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300294.SZ

STRONG SELLREMOVE

China Resources Boya Bio-pharmaceutical Group Co.,Ltd · Healthcare · China · $1.2B · Avg Vol: $19M/d

StockRank

P/E (TTM)

—

ROE

0.0%

D/E

0.0x

Dividend %

1.3%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

While operating in the healthcare sector, this blood products and biopharma business lacks the global scale and specialized CDMO capabilities required to capture high-margin outsourcing flows.

COMPANY DESCRIPTION

China Resources Boya Bio-pharmaceutical Group Co., Ltd. specializes in the research, development, and manufacture of blood products, including human albumin, immunoglobulins, and coagulation factors. Backed by the state-owned conglomerate China Resources Group, the company benefits from strong regulatory support and resources to expand its plasma collection stations. Its high-barrier manufacturing licenses and secure plasma supply chain establish a highly defensive competitive moat in China's tightly regulated biopharmaceutical market.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	408M	392M	256M	304M	-9.3%
EPS	0.13	0.07	0.12	0.03	-36.5%
Shares	504M	504M	504M	504M	0.0%
Debt	5M	4M	2M	10M	22.9%
Equity	1.1B	1.1B	1.1B	1.1B	1.2%
Op CF	88M	95M	44M	9M	-53.2%
Inv CF	-83M	2M	-96M	-101M	—
Fin CF	-13M	-35M	-45M	-23M	—

PRICE (1M)-4.2%

SMA 50SMA 200

$2.46

RSI (14)

62.7

52W High

$4.09

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

1.4%47.0

ROE

0.0%45.2

GP/Assets

10.2%26.2

Op. Margin

4.2%52.9

FCF/Assets

-7.4%31.8

Piotroski

—7.2

Int. Cover

50.0x91.4

D/E Ratio

0.01x88.3

Current Ratio

6.32x77.3

Value

P/E (TTM)

—0.4

EV/EBITDA

18.4x21.4

P/FCF

—N/A

P/B

1.1x75.9

P/S

4.5x44.0

Div Yield

1.3%36.3

Momentum

52W High %

60%40.1

RS 6M

-37%32.5

SMA 50/200

0.79x11.7

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

-78%3.9

FUNDAMENTALS

Market Cap

$1.2B

P/E (Forward)

12.8x

Gross Margin

47.5%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300294.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300294.SZ	China Resources Boya Bio-pharmaceutical Group Co.,Ltd(you)	$1.2B	16	STRONG SELL
688068.SS	Beijing Hotgen Biotech Co., Ltd.	$1.2B	12	STRONG SELL
2157.HK	Lepu Biopharma Co., Ltd.	$981M	15	STRONG SELL
688443.SS	Chongqing Genrix Biopharmaceutical Co., Ltd.	$1.5B	12	STRONG SELL
2616.HK	CStone Pharmaceuticals	$1.6B	14	STRONG SELL
688639.SS	Anhui Huaheng Biotechnology Co., Ltd.	$868M	17	STRONG SELL
300204.SZ	Staidson (Beijing) BioPharmaceuticals Co., Ltd.	$1.8B	16	STRONG SELL
688382.SS	InventisBio Co., Limited	$1.7B	12	STRONG SELL
2659.HK	Shanghai Bao Pharmaceuticals Co., Ltd.	$1.0B	10	STRONG SELL
2256.HK	Abbisko Cayman Limited	$826M	18	STRONG SELL

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.1%

China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) — Stock Score Summary

China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) has a MoatMap StockRank of 16/100 based on Quality (48/100), Value (31/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL. While operating in the healthcare sector, this blood products and biopharma business lacks the global scale and specialized CDMO capabilities required to capture high-margin outsourcing flows.

Key Financial Metrics

Price	$2.46
Market Cap	$1.2B
P/E (Forward)	12.79
Price/Book	1.12
Return on Equity	0.0%
Return on Invested Capital	1.4%
Debt/Equity	1.01
Gross Margin	47.5%
Operating Margin	4.2%
Revenue Growth	-40.1%
Dividend Yield	1.3%
Free Cash Flow	$-14M

China Resources Boya Bio-pharmaceutical Group Co.,Ltd operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is China Resources Boya Bio-pharmaceutical Group Co.,Ltd’s (300294.SZ) StockRank?: MoatMap’s StockRank for China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) is 16/100, with a Strong Sell signal. It is a composite of Quality (48), Value (31), and Momentum (25) factor ranks across MoatMap’s 19,000+ stock universe.
Does China Resources Boya Bio-pharmaceutical Group Co.,Ltd have an economic moat?: China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) has a Quality factor score of 48/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is China Resources Boya Bio-pharmaceutical Group Co.,Ltd a buy, hold, or sell?: MoatMap’s current signal for China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) is Strong Sell, based on a StockRank of 16/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is China Resources Boya Bio-pharmaceutical Group Co.,Ltd in?: China Resources Boya Bio-pharmaceutical Group Co.,Ltd (300294.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).